AHA In Brief: NeoRx Biostent
This article was originally published in The Gray Sheet
Executive Summary
NeoRx Biostent: Initial clinical results with cytochalasin B drug/catheter combination product find that 20% of patients with the treatment (six of 30) experienced post-procedure clinical events such as myocardial infarction, death, or revascularization, compared to 38% (five of 13) patients receiving a placebo, researchers report at the AHA conference in Orlando. Results were reported by Robert Wilensky, MD, University of Pennsylvania. A Phase II, 350-patient study is expected to begin in the second quarter of 1998, the company says. NeoRx is developing Biostent in collaboration with Schwarz Pharma A.G...